MI HB5367

Requires health insurance policies covering anticancer medications to ensure cost-sharing requirements (deductibles, copayments, coinsurance, out-of-pocket limits) for orally administered medications are no higher than those for intravenously administered or injected anticancer medications.

Mandates that treatment limitations on orally administered anticancer medications are no more restrictive than limitations on intravenously administered or injected anticancer medications.

Prohibits insurers from achieving compliance by increasing cost-sharing requirements, reclassifying benefits, or imposing more restrictive treatment limitations on any anticancer medications.

Defines key terms: "anticancer medication" as medication used to kill, slow, or prevent cancer cell growth; "cost-sharing requirement" as deductibles, copayments, coinsurance, out-of-pocket expenses, and annual/lifetime limits; "treatment limitation" as frequency, duration, or scope restrictions.

Applies to health insurance policies delivered, issued for delivery, or renewed in Michigan on or after the effective date of the act.